Pfizer, which was considering a split into two companies for more than two years, said it would not do so because the move would not create any shareholder value.
Johnson & Johnson said the U.S. Food and Drug Administration approved the company’s blockbuster psoriasis drug Stelara for adults with Crohn’s disease.
An experimental cannabis-derived drug has successfully treated children with severe epilepsy in a third late-stage clinical trial, sending shares in Britain’s GW Pharmaceuticals to a record high.
Vela Diagnostics said its test for the Zika virus had received “emergency use authorization” from the U.S. Food and Drug Administration.
On the same day that Pfizer announced it would not break into two companies, Waltham, Mass.-based PerkinElmer announced that it was breaking into two separate companies.
Five months after its acquisition by McKesson Corp. was finalized as part of a $1.2 billion deal, North Carolina-based Biologics Inc. announced it was terminating 132 employees, the Triangle Business Journal reported.
The U.S. Food and Drug Administration approved Amgen’s biosimilar version of AbbVie’s top-selling arthritis drug Humira.
Endo International Plc said Chief Executive Rajiv De Silva had stepped down and would be replaced by generics division head Paul Campanelli.
Six international health experts, including four from Europe, are to compete to become the next director general of the World Health Organization (WHO) after its current leader Margaret Chan ends her tenure in June 2017.
United Parcel Service Inc. said it began testing the use of drones for emergency deliveries of medical supplies with a flight in rural Massachusetts, which the company hopes will eventually lead to federal approval of drones as a regular delivery option.